Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.
Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.
The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.
Vector is Children's Hospital Boston's blog about research and innovation in pediatric and adult medicine. We report and comment on medical innovations and advances – from bench to bedside – touching on scientific, business and policy issues. Our ranks include science writers, physicians, lab researchers, market analysts and others inside and outside the hospital.
By Maureen McCarthy
Clinical excellence is the foundation of patient care. But at a recent TEDx Longwood event, Elaine C. Meyer, PhD, RN, co-founder and director of theInstitute for Professionalism and Ethical Practice at Boston Children's Hospital and an Associate Professor of Psychology at Harvard Medical School, offered insight on the other half of the health care equation: the human connection and the power of conversation.
Medtronic issues a warning letter to MiniMed Paradigm pump users after receiving reports that some patients had accidentally given themselves overdoses of insulin.
MASSDEVICE ON CALL — FDA medical device regulators reported this month that industry giant Medtronic (NYSE:MDT) issued a recall affecting nearly 560,000 units of its MiniMed Paradigm Infusion pumps.
Medtronic is not asking for the devices back, but is advising users to take extra care when programming their insulin dosage. The company has received reports that patients have accidentally programmed their insulin pumps to deliver the maximum bolus amount.
Sign up to get our free newsletters delivered straight to your inbox
The FDA report follows Medtronic's March 2014 letter to customers, in which the company cautioned users about accidental button pressing and advised that users always double-check their dosage on the pump's display.
Here's a look at some of the top legal news stories for medical device companies this week: ArthroCare ex-CEO faces 30-year sentence for fraud; Shareholders sue Edap following FDA slip; Ex-sales rep wins class action status in lawsuit against Stryker; Another Covidien shareholder sues over Medtronic deal; Respiratory rivals ResMed, BMC each tally wins in Trade Commission ruling